论文部分内容阅读
目的探讨头孢哌酮/舒巴坦对临床分离菌特别是MDR菌的抗菌活性。方法采用纸片扩散法测定头孢哌酮/舒巴坦对临床分离细菌的药物敏感性,结果判断按CLSI的头孢哌酮标准,并与其他抗生素的耐药率比较。结果头孢哌酮/舒巴坦9年间的耐药率增长不明显,对常见临床分离革兰阴性菌的耐药率为10.8%,明显低于除亚胺培南、阿米卡星外的抗生素(P=0),对临床治疗棘手MDR的鲍曼不动杆菌、铜绿假单胞菌、产超广谱β-内酰胺酶菌株和产碳青霉烯酶肠杆菌的耐药率分别为41.3%、13.5%、14%和59.3%,均低于三代头孢菌素、左氧氟沙星及β-内酰胺类/β-内酰胺类酶抑制剂复合制剂等。结论头孢哌酮/舒巴坦对感染病原特别是MDR菌较其他抗生素有更好的抗菌活性,是临床感染治疗的较好选择。
Objective To investigate the antibacterial activity of cefoperazone / sulbactam against clinical isolates, especially MDR. Methods The drug susceptibility of cefoperazone / sulbactam to clinically isolated bacteria was determined by disc diffusion method. The results were judged according to CLSI standard of cefoperazone and compared with those of other antibiotics. Results Cefoperazone / sulbactam showed no obvious increase in drug resistance rate in 9 years. The resistance rate to common clinical isolates of Gram-negative bacteria was 10.8%, which was significantly lower than that of imipenem and amikacin (P = 0). The resistance rates to Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum β-lactamase producing strains and carbapenemases producing Enterobacteriaceae in the treatment of thorny MDR were 41.3 %, 13.5%, 14% and 59.3% respectively, which were lower than the third generation cephalosporins, levofloxacin and β-lactams / β-lactamase inhibitors composite preparations. Conclusion Cefoperazone / sulbactam has better antibacterial activity against infectious pathogens, especially MDR bacteria than other antibiotics, which is a good choice for the treatment of clinical infection.